<DOC>
	<DOCNO>NCT02381951</DOCNO>
	<brief_summary>Parkinson 's disease affect 100'000 150'000 people France . Drug therapy ( L-Dopa drug ) effective improve motor symptom initial 'honeymoon period ' lasting year , motor symptom reoccur patient , impair gait walking . Spinal cord stimulation currently important therapeutic option treatment neuropathic pain . Experimental limit clinical data suggest technique might also use alleviate motor symptom improve walk Parkinsons patient . This exploratory study aim measure benefit spinal cord stimulation walk capacity small number Parkinsons patient adequately improve drug therapy alone .</brief_summary>
	<brief_title>Spinal Cord Stimulation Treatment Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Idiopathic Parkinson 's disease since 5 year Walking disorder freeze episode , insufficiently alleviate oral dopaminergic therapy and/or physiotherapy Atypical Parkinsonlike syndrome ( e.g . progressive supranuclear palsy ) Cognitive impairment ( MMSE &lt; 24 ) Psychiatric disease Contraindication surgery Neuropathic pain low limb lumbar region</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>